Literature DB >> 11964852

Pertussis: an old disease that is still with us.

U Heininger1.   

Abstract

Our knowledge of pathogenesis, clinical presentation and prevention of pertussis has improved substantially over recent years. We now better understand the function of long-known virulence factors for Bordetella pertussis, and genome sequencing has identified a multitude of new proteins; their functions are yet to be elucidated. Furthermore, improved diagnostic tools have revealed the broad spectrum of disease, and new insights into the host's immune response have been gained. Finally, the development, evaluation, licensing and implementation of several new acellular pertussis vaccines with high acceptance have changed the epidemiology of pertussis in many countries (i.e. a shift towards an increasing burden of disease in adolescent persons and adults). These developments are likely to have great impact on the daily practice not only of paediatricians, but also of general practitioners, internists, gynaecologists and many other specialists in adolescent and adult medicine. The present review provides an update on recent progress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11964852     DOI: 10.1097/00001432-200106000-00014

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  3 in total

1.  Severe and unrecognised: pertussis in UK infants.

Authors:  N S Crowcroft; R Booy; T Harrison; L Spicer; J Britto; Q Mok; P Heath; I Murdoch; M Zambon; R George; E Miller
Journal:  Arch Dis Child       Date:  2003-09       Impact factor: 3.791

2.  Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.

Authors:  Nathalie Mielcarek; Anne-Sophie Debrie; Severine Mahieux; Camille Locht
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

3.  Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.

Authors:  Hans O Hallander; Mikael Andersson; Lennart Gustafsson; Margaretha Ljungman; Eva Netterlid
Journal:  APMIS       Date:  2009-12       Impact factor: 3.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.